



## **New Documentary Shows How Occupational Back Injuries Risk Career of Noted Interventional Cardiologist Dr. Vijay Iyer**

*"Robotics Reducing the Burden of a Life in the Cath Lab" highlights how robotic technology is reducing the risks of further injuries caused by heavy protective apparel*

**WALTHAM, MA, September 16, 2015** – [Corindus Vascular Robotics, Inc. \[NYSE MKT: CVRS\]](#), a leading developer of precision vascular robotics, has released a new documentary film, "Robotics Reducing the Burden of a Life in the Cath Lab," to highlight the impact that protective lead apparel has on physicians practicing in catheterization labs and how robotics are employed to help solve these problems. The documentary features noted interventional cardiologist Dr. Vijay S. Iyer, who serves as Medical Director of Structural Heart Interventions at Gates Vascular Institute, Kaleida Health, in Buffalo, N.Y.

Dr. Iyer credits the [CorPath® System](#) with providing an alternative solution to constantly wearing heavy lead apparel to protect him from radiation. The CorPath System is the first and only FDA-cleared device for robotic-assisted PCI. The CorPath System protects interventional cardiologists from occupational radiation exposure and brings robotic-assisted precision to coronary angioplasty procedures.

"The radiation that comes from the X-ray machine is a constant threat to us, but by wearing the lead to protect myself, I ended up with serious back injuries," said Dr. Iyer. "My most recent surgery kept me out of work for six weeks, and many patients waited to have their procedure until I returned. I knew if the stress on my spine continued, the injury could put an end to my career as an interventional cardiologist."

Dr. Iyer has experienced multiple spinal disc herniations and has had four surgeries as a result of continual stresses on his musculoskeletal system from wearing traditional heavy, lead-lined apparel in the cath lab. Physicians wear the gear to protect themselves from the constant exposure to ionizing radiation during procedures in cath labs. Interventional cardiologists often perform multiple procedures each day, standing for hours, leaning over their patients while wearing a significant amount of weight, which can lead to musculoskeletal and orthopedic injuries.

"The CorPath System allows me to step away from the patient table, take my lead off, and sit down at a radiation shielded workstation where I have robotic control of the wire, balloon and stent," explained Dr. Iyer. "I'm no longer going to work every day dreading that back injury could make it the last day I'm an interventional cardiologist."

For Dr. Iyer, the CorPath System has offered him a chance to continue doing the work he enjoys without the stress and strain of heavy protective equipment that exacerbates his back problems. Musculoskeletal injuries such as Dr. Iyer's represent one type of occupational health risk linked to radiation exposure in the cath lab. Others potential risks that have been documented include cataracts, cancer, brain tumors, and thyroid diseases.

"Dr. Iyer's story highlights the serious risks linked to occupational radiation exposure in the cath lab that, if ignored, may cost many interventional cardiologists their health and careers," said David Handler, President and CEO of Corindus. "Hospital leadership and administrators need to leverage the technology

now available to create a work environment for physicians to preserve their health and perform their jobs safely and effectively. The CorPath System offers unique advantages of protection and robotic precision for PCI procedures."

The complete video can be accessed at <http://www.corindus.com/physician/dr-iyer's-story/>. For more information about the CorPath System, visit [www.corindus.com](http://www.corindus.com).

### **About Corindus Vascular Robotics, Inc.**

**Corindus Vascular Robotics, Inc.** is a global technology leader in robotic-assisted percutaneous coronary interventions (PCIs). The company's FDA-cleared CorPath System is the first medical device that offers interventional cardiologists PCI procedure control from a radiation protective interventional cockpit. With the CorPath System, Corindus Vascular Robotics brings robotic precision to PCI procedures to help optimize clinical outcomes and minimize the costs associated with complications through improper stent placement with manual PCI procedures. Corindus stands behind its product with its unique \$1,000 hospital credit "One Stent Program." For additional information, visit [www.corindus.com](http://www.corindus.com), and follow @CorindusInc.

*Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus Vascular Robotics to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus Vascular Robotics' beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside the control of Corindus Vascular Robotics. Examples of such statements include statements regarding the potential benefits of the CorPath System and robotic-assisted PCI for hospitals, patients and physicians. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others: the rate of adoption of the CorPath System and the rate of use of CorPath Cassettes; risks associated with market acceptance, including pricing and reimbursement; Corindus Vascular Robotics' ability to enforce its intellectual property rights; the need for additional funds to support operations; the ability to manage expenses and cash flow; factors relating to engineering, regulatory, manufacturing, sales and customer service challenges; potential safety and regulatory issues that could slow or suspend sales; and the effect of credit, financial and economic conditions on capital spending by potential customers. More information on potential factors that could affect Corindus Vascular Robotics' financial results is included from time to time in the "Forward-Looking Statements," "Risk Factors," and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Corindus Vascular Robotics' periodic and current filings with the SEC, as well as those discussed under the "Risk Factors" and "Forward-Looking Statements" section of Corindus Vascular Robotics' Annual Report on Form 10-K filed with the SEC on March 30, 2015 and available on its website at <http://www.corindus.com/about-corindus/investor-relations>. Forward-looking statements speak only as of the date they are made and Corindus Vascular Robotics undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, that occur after that date.*

###

### **Media Contacts:**

Corindus Vascular Robotics, Inc.

Brett Prince

(508) 653-3335 ext. 231

[brett.prince@corindus.com](mailto:brett.prince@corindus.com)

Katie Toomey

(315) 529-3947

[corindus@knbpr.com](mailto:corindus@knbpr.com)